Literature DB >> 1358128

Clinical management of clozapine patients in relation to efficacy and side-effects.

D Naber1, R Holzbach, C Perro, H Hippius.   

Abstract

Medical charts of 480 schizophrenic in-patients (581 treatments) were analysed to evaluate the efficacy and side-effects of clozapine. Clozapine treatment lasted for mean 49 (s.d. 38) days. Of the sample, 11.0% showed worsening or no change, 31.5% slight improvement, 53.0% marked improvement and 4.5% almost total reduction of symptoms. At least one major side-effect occurred in 68.0% of patients. A combination of clozapine with classical neuroleptics, antidepressants, benzodiazepines or lithium is tolerated by most patients, but increases the incidence of some side-effects. Clozapine treatment had to be discontinued because of severe side-effects in 8.6% of patients. In 81 schizophrenic out-patients, clozapine significantly reduced the days of in-patient treatment and number of hospital readmissions. Two patients developed leucopenia but had no complications after clozapine withdrawal. This study indicates a satisfactory benefit/risk ratio and compliance in most of the patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1358128

Source DB:  PubMed          Journal:  Br J Psychiatry Suppl        ISSN: 0960-5371


  34 in total

1.  Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study.

Authors:  J P van Vugt; S Siesling; M Vergeer; E A van der Velde; R A Roos
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-07       Impact factor: 10.154

2.  [Considerations in the combination of clozapine and benzodiazepines].

Authors:  R Rupprecht; M Soyka; R Grohmann; E Rüther; H-J Möller
Journal:  Nervenarzt       Date:  2004-09       Impact factor: 1.214

3.  Is clozapine worth its cost?

Authors:  F R Frankenburg
Journal:  Pharmacoeconomics       Date:  1993-11       Impact factor: 4.981

Review 4.  Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009.

Authors:  Juan A Gallego; John Bonetti; Jianping Zhang; John M Kane; Christoph U Correll
Journal:  Schizophr Res       Date:  2012-04-24       Impact factor: 4.939

5.  Safety and tolerability of antipsychotic polypharmacy.

Authors:  Juan A Gallego; Jimmi Nielsen; Marc De Hert; John M Kane; Christoph U Correll
Journal:  Expert Opin Drug Saf       Date:  2012-05-08       Impact factor: 4.250

Review 6.  Antidepressive effects of traditional and second generation antipsychotics: a review of the clinical data.

Authors:  Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-04       Impact factor: 5.270

Review 7.  A translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacy.

Authors:  William G Honer; Ric M Procyshyn; Eric Y H Chen; G William MacEwan; Alasdair M Barr
Journal:  J Psychiatry Neurosci       Date:  2009-11       Impact factor: 6.186

8.  Clozapine: an appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia.

Authors:  A Fitton; P Benfield
Journal:  Pharmacoeconomics       Date:  1993-08       Impact factor: 4.981

Review 9.  The catatonia conundrum: evidence of psychomotor phenomena as a symptom dimension in psychotic disorders.

Authors:  Gabor S Ungvari; Stanley N Caroff; Jozsef Gerevich
Journal:  Schizophr Bull       Date:  2009-09-23       Impact factor: 9.306

Review 10.  Drug treatment of resistant schizophrenia. Limitations and recommendations.

Authors:  A E Farmer; A Blewett
Journal:  Drugs       Date:  1993-03       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.